Cardiology

The interaction between systolic blood pressure (SBP) and the effects of empagliflozin in patients with heart failure with reduced ejection fraction (HFrEF).

SGLT2 inhibitors are not created equal; patient-specific characteristics need to be considered for best efficacy.

Is weight loss always as beneficial as we think?

This review examines the differing arguments recent studies have made regarding blood pressure goals and cardiovascular risk. 

CREDENCE trial shows that canagliflozin, an SGLT2 inhibitor, lowers the risk of cardiovascular and renal events in patients with T2DM, regardless of prior history of heart failure. 

Are the mortality and cardiovascular benefits of SGLT-2 inhibitors limited to patients with type 2 diabetes who have established cardiovascular disease and renal disease?

Dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1RAs create an additive effect for increased anti-inflammation and vascular protection.

The FDA has approved empagliflozin Breakthrough therapy for patients with heart failure with preserved ejection fraction (HFpEF).

GLP-1 receptor agonists are a pharmacologic treatment of type 2 diabetes with potential cardiorenal benefits.

Every comorbidity related to diabetes causes life expectancy to plummet and medical costs to soar.